## Vincent C Emery

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/427853/publications.pdf

Version: 2024-02-01

123 papers

8,711 citations

45 h-index 90 g-index

124 all docs

124 docs citations

times ranked

124

7943 citing authors

#	Article	IF	CITATIONS
1	Digital technologies in the public-health response to COVID-19. Nature Medicine, 2020, 26, 1183-1192.	30.7	695
2	Vaccination against cytomegalovirus: Still at base camp?. American Journal of Transplantation, 2018, 18, 2847-2848.	4.7	1
3	Towards an ultra-rapid smartphone- connected test for infectious diseases. Scientific Reports, 2017, 7, 11971.	3.3	42
4	Maternal Highly Active Antiretroviral Therapy Reduces Vertical Cytomegalovirus Transmission But Does Not Reduce Breast Milk Cytomegalovirus Levels. AIDS Research and Human Retroviruses, 2017, 33, 332-338.	1.1	8
5	Cytomegalovirus in pregnancy and the neonate. F1000Research, 2017, 6, 138.	1.6	28
6	Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. PLoS Pathogens, 2017, 13, e1006299.	4.7	12
7	Compartmentalized dynamics of cytomegalovirus replication in treated congenital infection. Journal of Clinical Virology, 2016, 82, 152-158.	3.1	10
8	Vertical Cytomegalovirus Transmission From HIV-Infected Women Randomized to Formula-Feed or Breastfeed Their Infants. Journal of Infectious Diseases, 2016, 213, 992-998.	4.0	25
9	Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy. PLoS ONE, 2016, 11, e0163722.	2.5	36
10	Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients. Journal of General Virology, 2015, 96, 131-143.	2.9	30
11	Restimulating Interest in Cytomegalovirus as a Cofactor for HIV Infection. Journal of Infectious Diseases, 2015, 211, 169-171.	4.0	8
12	Maternal Valacyclovir and Infant Cytomegalovirus Acquisition: A Randomized Controlled Trial among HIV-Infected Women. PLoS ONE, 2014, 9, e87855.	2.5	40
13	Compartmentalized Cytomegalovirus Replication and Transmission in the Setting of Maternal HIV-1 Infection. Clinical Infectious Diseases, 2014, 58, 564-572.	5.8	44
14	Taming the Transplantation Troll by Targeting Terminase. New England Journal of Medicine, 2014, 370, 1844-1846.	27.0	28
15	<scp>CMV</scp> infected or not <scp>CMV</scp> infected: That is the question. European Journal of Immunology, 2013, 43, 886-888.	2.9	7
16	The "Silent―Global Burden of Congenital Cytomegalovirus. Clinical Microbiology Reviews, 2013, 26, 86-102.	13.6	771
17	Management of cytomegalovirus infection in haemopoietic stem cell transplantation. British Journal of Haematology, 2013, 162, 25-39.	2.5	92
18	Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Reviews in Medical Virology, 2013, 23, 97-125.	8.3	60

#	Article	IF	CITATIONS
19	Acute Cytomegalovirus Infection Is Associated with Increased Frequencies of Activated and Apoptosis-Vulnerable T Cells in HIV-1-Infected Infants. Journal of Virology, 2012, 86, 11373-11379.	3.4	28
20	Cytomegalovirus: recent progress in understanding pathogenesis and control. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 401-405.	0.5	17
21	Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients. Transplantation, 2012, 93, 1075-1085.	1.0	129
22	Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy. Journal of Clinical Virology, 2012, 54, 56-60.	3.1	12
23	Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation. Journal of Clinical Virology, 2012, 54, 125-129.	3.1	21
24	Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2012, 129, 1349-1356.e3.	2.9	30
25	Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy. American Journal of Transplantation, 2012, 12, 2457-2464.	4.7	154
26	Immunotherapy and Vaccination After Transplant: The Present, the Future. Hematology/Oncology Clinics of North America, 2011, 25, 215-229.	2.2	1
27	Inflammation in common variable immunodeficiency is associated with a distinct CD8+ response to cytomegalovirus. Journal of Allergy and Clinical Immunology, 2011, 127, 1385-1393.e4.	2.9	29
28	Cytomegalovirus quantification: Where to next in optimising patient management?. Journal of Clinical Virology, 2011, 51, 223-228.	3.1	27
29	Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet, The, 2011, 377, 1256-1263.	13.7	352
30	Could a vaccine against immune-evading cytomegalovirus become a reality?. Expert Review of Vaccines, 2011, 10, 1109-1111.	4.4	3
31	Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation. Transplantation, 2011, 92, 1181-1187.	1.0	64
32	Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation, 2010, 90, 564-570.	1.0	57
33	Extensive human cytomegalovirus (HCMV) genomic DNA in the renal tubular epithelium early after renal transplantation: Relationship with HCMV DNAemia and longâ€ŧerm graft function. Journal of Medical Virology, 2010, 82, 85-93.	5.0	10
34	Sequence flexibility of the immunodominant HLA A*0201 restricted ppUL83 CD8 Tâ€eell epitope of human cytomegalovirus. Journal of Medical Virology, 2010, 82, 94-103.	5.0	7
35	The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae, 2010, 1, 4.	2.7	18
36	Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4 <sup>+</sup> perforin expressing T cells enriched for human cytomegalovirus specificity and an effectorâ€memoryphenotype. British Journal of Haematology, 2010, 148, 274-284.	2.5	11

#	Article	IF	CITATIONS
37	Management of postâ€transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines. British Journal of Haematology, 2010, 149, 693-705.	2.5	191
38	Diagnosis of postâ€transplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS Guidelines. British Journal of Haematology, 2010, 149, 675-692.	2.5	211
39	Immunotherapy and Vaccination After Transplant: The Present, the Future. Infectious Disease Clinics of North America, 2010, 24, 515-529.	5.1	4
40	Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy. Journal of Clinical Virology, 2010, 49, 32-36.	3.1	24
41	Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. Journal of General Virology, 2010, 91, 1535-1546.	2.9	164
42	Impact of Genetic Polymorphisms in Cytomegalovirus Glycoprotein B on Outcomes in Solidâ€Organ Transplant Recipients with Cytomegalovirus Disease. Clinical Infectious Diseases, 2009, 49, 1160-1166.	5.8	96
43	Acute cytomegalovirus infection in Kenyan HIV-infected infants. Aids, 2009, 23, 2173-2181.	2.2	80
44	The detection of cytomegalovirus DNA in maternal plasma is associated with mortality in HIV-1-infected women and their infants. Aids, 2009, 23, 117-124.	2.2	40
45	Genotypic analysis of two hypervariable human cytomegalovirus genes. Journal of Medical Virology, 2008, 80, 1615-1623.	5.0	54
46	Differential Effects of Prednisolone and Azathioprine on the Development of Human Cytomegalovirus Replication Post Liver Transplantation. Transplantation, 2007, 84, 605-610.	1.0	14
47	Facing the Facts: The Indirect Effects of Cytomegalovirus. Transplantation, 2007, 84, S7-S10.	1.0	10
48	Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transplantation, 2007, 13, 130-135.	2.4	27
49	Cytomegalovirus in transplantation? challenging the status quo. Clinical Transplantation, 2007, 21, 149-158.	1.6	245
50	The ESCRT machinery is not required for human cytomegalovirus envelopment. Cellular Microbiology, 2007, 9, 2955-2967.	2.1	65
51	Detection of cytomegalovirus in human placental cells by polymerase chain reaction. Apmis, 2006, 114, 764-771.	2.0	22
52	Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis. Proceedings of the Royal Society B: Biological Sciences, 2006, 273, 1961-1967.	2.6	14
53	Susceptibility of porcine cytomegalovirus to antiviral drugs. Journal of Antimicrobial Chemotherapy, 2004, 53, 975-980.	3.0	23
54	Genetic content of wild-type human cytomegalovirus. Journal of General Virology, 2004, 85, 1301-1312.	2.9	500

#	Article	IF	CITATIONS
55	The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune response. Journal of Medical Virology, 2004, 72, 187-193.	5.0	6
56	Sequence variability of the αâ€chemokine UL146 from clinical strains of human cytomegalovirus. Journal of Medical Virology, 2004, 74, 573-579.	5.0	41
57	A Randomized, Controlled Trial Comparing Ganciclovir to Ganciclovir Plus Foscarnet (Each at Half) Tj ETQq1 1 0.7 Infectious Diseases, 2004, 189, 1355-1361.	784314 rgl 4.0	3T /Overlock 87
58	Evolution of hepatitis B virus during primary infection in humans: Transient generation of cytotoxic T-cell mutants. Gastroenterology, 2004, 127, 1131-1138.	1.3	23
59	Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet, The, 2004, 363, 2116-2121.	13.7	201
60	Multidrug Resistance in Human Cytomegalovirus. , 2004, , 379-391.		0
61	Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes: the Journal of the IHMF, 2004, 11, 77-86.	0.3	34
62	Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides. Journal of Medical Virology, 2003, 70, 86-90.	5.0	38
63	Porcine cytomegalovirus in pigs being bred for xenograft organs: progress towards control. Xenotransplantation, 2003, 10, 142-148.	2.8	52
64	Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in hematological patients. Seminars in Hematology, 2003, 40, 154-162.	3.4	33
65	Clinical xenotransplantation. Lancet, The, 2003, 362, 1421.	13.7	1
66	Human Cytomegalovirus Seropositivity Is Associated With Impaired Vascular Function. Circulation, 2003, 108, 678-683.	1.6	105
67	Two novel spliced genes in human cytomegalovirus. Journal of General Virology, 2003, 84, 1117-1122.	2.9	126
68	Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in hematological patients. Seminars in Hematology, 2003, 40, 154-162.	3 <b>.</b> 4	25
69	Homology between the human cytomegalovirus RL11 gene family and human adenovirus E3 genes. Journal of General Virology, 2003, 84, 657-663.	2.9	79
70	The Prognostic Value of a Single Hepatitis C Virus RNA Load Measurement Taken Early after Human Immunodeficiency Virus Seroconversion. Journal of Infectious Diseases, 2002, 186, 470-476.	4.0	11
71	Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. Journal of Antimicrobial Chemotherapy, 2002, 49, 359-366.	3.0	24
72	Human Cytomegalovirus (HCMV) Replication Dynamics in HCMVâ€Naive and â€Experienced Immunocompromised Hosts. Journal of Infectious Diseases, 2002, 185, 1723-1728.	4.0	112

#	Article	IF	Citations
73	Cd8 Cytotoxic Lymphocyte Responses against Cytomegalovirus in Renal Transplant Patients and Healthy Individuals. Clinical Science, 2002, 103, 28P-29P.	0.0	0
74	Molecular diagnosis of cytomegalovirus disease. , 2002, , 467-473.		0
75	Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. Aids, 2002, 16, 2129-2135.	2.2	28
76	Focus on New Drugs in Development Against Human Cytomegalovirus. Drugs, 2002, 62, 1853-1858.	10.9	46
77	Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet, The, 2002, 360, 1546-1551.	13.7	30
78	Cytomegalovirus and the Aging Population. Drugs and Aging, 2001, 18, 927-933.	2.7	20
79	Prophylaxis for CMV shouldnot now replace pre-emptive therapy in solid organ transplantation. Reviews in Medical Virology, 2001, 11, 83-86.	8.3	84
80	Quantity of cytomegalovirus DNA in different leukocyte populations during active infection in vivo and the presence of gB and UL18 transcripts. Journal of Medical Virology, 2001, 64, 283-289.	5.0	38
81	Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. Journal of Medical Virology, 2001, 65, 218-224.	<b>5.</b> O	94
82	Quantitation of Porcine Cytomegalovirus in Pig Tissues by PCR. Journal of Clinical Microbiology, 2001, 39, 1155-1156.	3.9	44
83	Kinetics of Acute Hepatitis B Virus Infection in Humans. Journal of Experimental Medicine, 2001, 193, 847-854.	8.5	178
84	Human Herpesviruses 6 and 7 in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 2001, 32, 1357-1360.	5.8	34
85	Cytomegalovirus (CMV) Resistance to Antivirals. American Journal of Transplantation, 2001, 1, 307-312.	4.7	57
86	Newer human herpesviruses in transplantation. Current Opinion in Organ Transplantation, 2000, 5, 203-209.	1.6	1
87	A non-radioisotopic quantitative competitive polymerase chain reaction method: application in measurement of human herpesvirus 7 load. Journal of Virological Methods, 2000, 87, 177-181.	2.1	14
88	Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. Aids, 2000, 14, 1163-1170.	2.2	98
89	Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet, The, 2000, 355, 2032-2036.	13.7	496
90	PROSPECTIVE STUDY OF HUMAN BETAHERPESVIRUSES AFTER RENAL TRANSPLANTATION. Transplantation, 2000, 69, 2400-2404.	1.0	126

#	Article	IF	Citations
91	TUNING TO THE RIGHT FREQUENCY: CYTOTOXIC T LYMPHOCYTES AND CYTOMEGALOVIRUS. Transplantation, 2000, 69, 2241-2242.	1.0	2
92	A Longitudinal Study of Human Papillomavirus 16 Positivity in the Development of Lower Genital Intraepithelial Neoplasia in Immunosuppressed Women. Journal of Lower Genital Tract Disease, 1999, 3, 163-170.	1.9	0
93	Detection of human retrovirus 5 in patients with arthritis and systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 448-454.	6.7	58
94	Interactions between ?-herpesviruses and human immunodeficiency virus in vivo: Evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6., 1999, 57, 278-282.		47
95	Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG)., 1999, 58, 182-187.		60
96	Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus. Journal of Medical Virology, 1999, 59, 496-501.	5.0	146
97	The Dynamics of Human Cytomegalovirus Replication in Vivo. Journal of Experimental Medicine, 1999, 190, 177-182.	8.5	244
98	Viral Dynamics during Active Cytomegalovirus Infection and Pathology. Intervirology, 1999, 42, 405-411.	2.8	28
99	Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. Aids, 1999, 13, 1203-1206.	2.2	93
100	The U69 Gene of Human Herpesvirus 6 Encodes a Protein Kinase Which Can Confer Ganciclovir Sensitivity to Baculoviruses. Journal of Virology, 1999, 73, 3284-3291.	3.4	60
101	A multiplex PCR assay for the simultaneous detection of human herpesvirus 6 and human herpesvirus 7, with typing of HHV-6 by enzyme cleavage of PCR products. Journal of Virological Methods, 1998, 70, 29-36.	2.1	45
102	Quantitative differences in the distribution of zidovudine resistance mutations in multiple post-mortem tissues from AIDS patients. , 1998, 55, 138-146.		6
103	Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. Aids, 1998, 12, 605-611.	2.2	54
104	Baculovirus Vectors. Springer Protocols, 1998, , 219-233.	0.3	0
105	Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. Aids, 1997, 11, 889-893.	2.2	146
106	Development of a quantitative competitive polymerase chain reaction for human herpesvirus 8. Journal of Virological Methods, 1997, 64, 19-26.	2.1	34
107	Development of a point mutation assay for the detection of human cytomegalovirus UL97 mutations associated with ganciclovir resistance. Journal of Virological Methods, 1997, 68, 225-234.	2.1	24
108	Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. Aids, 1996, 10, 1515-1520.	2.2	111

#	Article	IF	CITATIONS
109	Predicted $\hat{l}$ ±-helix/ $\hat{l}^2$ -sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7. Biochemical Journal, 1996, 319, 229-239.	3.7	44
110	Detection of human cytomegalovirus polymerase chain reaction products using oligonucleotide probes directly conjugated to alkaline phosphatase. Journal of Virological Methods, 1996, 61, 145-150.	2.1	2
111	Production of Plaques in Monolayer Tissue Cultures by Single Particles of an Animal Virus. , 1996, 6, 61-64.		0
112	Respiratory Virus and Mycoplasmal Infections in the Immunocompromised., 1996,, 359-381.		0
113	Distinct HIV-1 long terminal repeat quasispecies present in nervous tissues compared to that in lung, blood and lymphoid tissues of an AIDS patient. Aids, 1995, 9, 675-684.	2.2	72
114	$\hat{I}^2$ -Sheet secondary structure of an LDL receptor domain from complement factor I by consensus structure predictions and spectroscopy. FEBS Letters, 1995, 371, 199-203.	2.8	15
115	Hypothetical structure of the membrane-associated E5 oncoprotein of human papillomavirus type 16. Biochemical Society Transactions, 1994, 22, 439S-439S.	3.4	15
116	Sequence microheterogeneity in the long control region of clinical isolates of human papillomavirus type 16. Journal of Medical Virology, 1993, 39, 267-272.	5.0	13
117	Sequence variation within the human immunodeficiency virus V3 loop at seroconversion. Journal of Medical Virology, 1993, 41, 270-274.	5.0	11
118	The use of baculoviruses as expression vectors. Applied Biochemistry and Biotechnology, 1993, 42, 137-159.	2.9	72
119	PROVISION OF PROGNOSTIC INFORMATION IN IMMUNOCOMPROMISED PATIENTS BY ROUTINE APPLICATION OF THE POLYMERASE CHAIN REACTION FOR CYTOMEGALOVIRUS. Transplantation, 1993, 56, 867-871.	1.0	106
120	Eliminating PCR contamination: is UV irradiation the answer?. Journal of Virological Methods, 1991, 33, 375-382.	2.1	38
121	A T-cell protein which recognizes a palindromic DNA sequence in the negative regulatory element of the HIV-1 long terminal repeat with homology to steroid/thyroid hormone receptor binding sites. Biochemical Society Transactions, 1990, 18, 555-556.	3.4	1
122	The development of multiple expression vectors for high level synthesis of eukaryotic proteins: expression of LCMV-N and AcNPV polyhedrin protein by a recombinant baculovirus. Protein Engineering, Design and Selection, 1987, 1, 359-366.	2.1	75
123	HHV-6A, 6B, and 7: persistence in the population: epidemiology and transmission., 0,, 875-882.		12